Clinical Trials · NCT00175383

Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer

Name: Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/AGonadorelin

Phase: N/A
Recruitment status: Completed
Sponsor: University of British Columbia
Enrollment: 100
Start date: Jun 2004
Locations: 1 site, Canada
Primary endpoint: The primary objective of this study is the median time to testosterone recovery in patients receiving 6 X 1-month or 2 X 3-month LHrH preparations and TPIP as radical treatment for limited stage prostate cancer.

View Gonadorelin compound reference